Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder characterized by chronic or relapsing eczematous lesions with intense pruritus and discomfort. Affected patients often experience significant impairment in their quality of life, and the treatment of moderate-to-severe AD forms remains challenging. In the past few decades, increasing knowledge on the AD pathogenesis has driven the development of novel targeted therapies. Interleukin (IL)-13 plays a central and pleiotropic role in AD pathogenesis, contributing directly or indirectly to epidermal barrier disfunction, type-2 inflammation, dysbiosis, fibrosis, and itch response. For this reason, agents selectively targeting IL-13, such as lebrikizumab, emerged as a potential therapy for AD. This article reviews the current evidence about lebrikizumab in the management of AD. The phase II and phase III trials seem to corroborate efficacy of lebrikizumab in the treatment of moderate-to-severe AD, as shown by significant improvement of Eczema Area and Severity Index, body surface area, and pruritus scores. Also, lebrikizumab demonstrated favorable safety and tolerability profiles, with the majority of patients experiencing no significant adverse events. Lebrikizumab seems to be a promising emerging targeted biological agent for patients with moderate-to-severe AD. More data on the long-term efficacy and safety, head-to-head comparisons with other agents, and real-world evidence will help to clarify its place in therapy in AD.

特应性皮炎 (AD) 是一种常见的异质性炎症性皮肤病，其特征是慢性或复发性湿疹皮损，伴有剧烈瘙痒和不适。受影响的患者的生活质量通常会受到严重损害，中度至重度 AD 形式的治疗仍然具有挑战性。在过去的几十年里，对 AD 发病机制的了解不断增加，推动了新型靶向治疗的发展。白细胞介素 (IL)-13 在 AD 发病机制中发挥着重要的多效性作用，直接或间接导致表皮屏障功能障碍、2 型炎症、生态失调、纤维化和瘙痒反应。因此，选择性靶向 IL-13 的药物（例如 lebrikizumab）成为 AD 的潜在疗法。本文回顾了有关 lebrikizumab 治疗 AD 的当前证据。II期和III期试验似乎证实了lebrikizumab治疗中重度AD的疗效，湿疹面积和严重程度指数、体表面积和瘙痒评分的显着改善表明了这一点。此外，lebrikizumab 表现出良好的安全性和耐受性，大多数患者没有出现明显的不良事件。Lebrikizumab 似乎是一种有前途的新兴靶向生物制剂，适用于中重度 AD 患者。更多关于长期疗效和安全性的数据、与其他药物的头对头比较以及现实世界的证据将有助于阐明其在 AD 治疗中的地位。